A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Recruiting · NCT07545122 · Registry updated 2026-10-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-10-08 | NCT07545122 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Context Therapeutics Inc. | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Calvary Mater Hospital Newcastle | Newcastle | Australia | 1 |
| Crown Princess Mary Cancer Centre Westmead Hospital | Westmead | Australia | 1 |
| Linear Clinical Research | Perth | Australia | 3 |
| Olivia Newton John Cancer Centre | Heidelberg | Australia | 1 |
| Sydney Adventist Hospital | Wahroonga | Australia | 17 |
| Tasman Oncology Research | Gold Coast | Australia | 1 |